research use only
Cat.No.S8921
| Related Targets | VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit |
|---|---|
| Other EGFR Inhibitors | Lazertinib (YH25448) Icotinib Hydrochloride Sunvozertinib AG-490 AG-1478 Canertinib (CI-1033) WZ4002 Poziotinib (NOV120101, HM781-36B) Rociletinib (CO-1686) Genistein |
|
In vitro |
Ethanol : 30 mg/mL Water : 20 mg/mL
DMSO
: 15 mg/mL
(27.64 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 542.68 | Formula | C30H38N8O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2664214-60-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1CCCOC2=C(C=N[N]2C)C3=NC(=CC(=C3)C(=O)N=C4NC5=C(C=C(CN6CCN(C)CC6)C=C5)N4C1)C | ||
| Targets/IC50/Ki |
EGFRdel19 T790M C797S
(anti-proliferation potency) 0.2 nM
EGFRdel19 T790M C797S
(biomarker potency) 0.6 nM
|
|---|---|
| In vitro |
BI-4020 is a noncovalent, macrocyclic TKI, which inhibits not only the triple mutant EGFRdel19 T790M C797S variant but also the double mutant EGFRdel19 T790M and primary mutant EGFRdel19 while sparing activity against EGFRwt. |
| In vivo |
BI-4020 shows high potency on EGFR mutant cells, high kinome selectivity, and good DMPK properties, which leads to tumor regressions in the human PC-9 (EGFRdel19 T790M C797S) triple mutant NSCLC xenograft model in mice. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.